z-logo
open-access-imgOpen Access
Succination inactivates gasdermin D and blocks pyroptosis
Author(s) -
Fiachra Humphries,
Liraz Shmuel-Galia,
Natália Ketelut-Carneiro,
Sheng Li,
Bingwei Wang,
Venkatesh V. Nemmara,
Ruth Wilson,
Zhaozhao Jiang,
Farnaz Khalighinejad,
Khaja Muneeruddin,
Scott A. Shaffer,
Ranjan Dutta,
Carolina Ionete,
Scott Pesiridis,
Shuo Yang,
Paul R. Thompson,
Katherine A. Fitzgerald
Publication year - 2020
Publication title -
science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 12.556
H-Index - 1186
eISSN - 1095-9203
pISSN - 0036-8075
DOI - 10.1126/science.abb9818
Subject(s) - pyroptosis , dimethyl fumarate , cysteine , programmed cell death , chemistry , immune system , microbiology and biotechnology , apoptosis , biochemistry , biology , enzyme , immunology , multiple sclerosis
Fumarate targets pyroptosis A form of inflammatory cell death called pyroptosis depends on the caspase-mediated cleavage of gasdermin D (GSDMD), the fragments of which assemble into permeability pores that then kill the cell. The mechanisms regulating this important cellular process are not yet fully understood. Humphrieset al. now report that the tricarboxylic acid cycle intermediate fumarate can act as an inhibitor of pyroptosis (see the Perspective by Pickering and Bryant). Both endogenous fumarate and exogenously delivered dimethyl fumarate (DMF) convert the cysteines in GSDMD to S-(2-succinyl)-cysteines (a process called succination) to prevent its interaction with caspases and subsequent processing and activation. Administration of DMF to mice alleviated inflammation in models of multiple sclerosis and familial Mediterranean fever. These findings may explain the efficacy of DMF as a treatment for multiple sclerosis and other inflammatory diseases and offer insights into future anti-inflammatory drug design.Science , this issue p.1633 ; see also p.1564

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom